Market open
Werewolf Therapeutics/$HOWL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Ticker
$HOWL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
46
ISIN
US95075A1079
Website
HOWL Metrics
BasicAdvanced
$50M
-
-$1.67
0.49
-
Price and volume
Market cap
$50M
Beta
0.49
52-week high
$5.73
52-week low
$0.60
Average daily volume
317K
Financial strength
Current ratio
8.095
Quick ratio
7.888
Long term debt to equity
62.125
Total debt to equity
64.589
Interest coverage (TTM)
-15.14%
Management effectiveness
Return on assets (TTM)
-32.66%
Return on equity (TTM)
-82.81%
Valuation
Price to revenue (TTM)
42.864
Price to book
0.87
Price to tangible book (TTM)
0.87
Price to free cash flow (TTM)
-0.817
Growth
Revenue change (TTM)
-92.95%
Earnings per share change (TTM)
49.46%
3-year earnings per share growth (CAGR)
-28.68%
What the Analysts think about HOWL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Werewolf Therapeutics stock.
HOWL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HOWL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HOWL News
AllArticlesVideos
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
GlobeNewsWire·3 days ago
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·1 week ago
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Werewolf Therapeutics stock?
Werewolf Therapeutics (HOWL) has a market cap of $50M as of May 16, 2025.
What is the P/E ratio for Werewolf Therapeutics stock?
The price to earnings (P/E) ratio for Werewolf Therapeutics (HOWL) stock is 0 as of May 16, 2025.
Does Werewolf Therapeutics stock pay dividends?
No, Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Werewolf Therapeutics dividend payment date?
Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders.
What is the beta indicator for Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.